Choline Deficiency and Eye Health: Current Evidence
The relationship between choline deficiency and clinically significant eye disease remains uncertain and not yet established for routine clinical practice. According to the most recent ESPEN micronutrient guidelines (2022), whether age-related macular degeneration should be considered a hallmark of choline and betaine deficiency "remains to be established" 1.
What the Guidelines Tell Us
The 2022 ESPEN guidelines clearly identify the established clinical manifestations of choline deficiency as:
- Non-alcoholic liver steatosis/steatohepatitis (confirmed by imaging or elevated liver enzymes)
- Subclinical muscle damage with elevated creatine phosphokinase levels 1
Notably absent from this list: any definitive eye-related pathology.
The guidelines explicitly state that choline measurement should be considered only in patients on home parenteral nutrition who develop unexplained liver steatosis or muscle damage—not for eye complaints 1.
Emerging Research Evidence
While guidelines remain cautious, recent research suggests potential connections:
Glaucoma
- A 2025 study found that supplementing B vitamins and choline provides neuroprotection in glaucoma models, with dysregulation of one-carbon metabolism (which involves choline) occurring early in disease 2
- A 2009 animal study showed reduced choline levels in the visual cortex of glaucomatous rats 3
- However, these are experimental findings not yet translated to clinical recommendations
Retinal Development
- Choline plays roles in retinal development and differentiation 4
- A 2022 mouse study showed choline supplementation enhanced spatial memory but had only minor contributions to retina function 5
- A 2019 review emphasized choline's role in infant eye development, but focused on developmental rather than deficiency contexts 6
Contradictory Finding
- A 2022 NHANES study found higher dietary choline intake was associated with increased odds of diabetic retinopathy in females (OR 2.14,95% CI 1.38-3.31), suggesting excess rather than deficiency may be problematic in certain contexts 7
Clinical Bottom Line
For practical clinical decision-making:
- Do not routinely screen for or treat choline deficiency based on eye symptoms alone
- The established deficiency manifestations are hepatic and muscular, not ocular 1
- If choline deficiency is suspected (patients on long-term parenteral nutrition, severe malnutrition), look for liver steatosis and muscle damage first
- Eye-related benefits of choline are primarily relevant during fetal development and early life, not as a treatment for adult eye disease 6, 8, 9
When to Consider Choline Status
Only in these specific scenarios:
- Patients on home parenteral nutrition with unexplained liver disease 1
- Cystic fibrosis patients (established deficiency risk) 1
- Pregnancy/lactation for fetal development (not maternal eye health) 8, 9
Common Pitfall to Avoid
Do not extrapolate the emerging glaucoma research 2 into clinical practice yet—this represents experimental neuroprotection research, not established deficiency treatment. The study used combined B-vitamin supplementation, making it impossible to isolate choline's specific contribution.
In summary: Current high-quality guidelines do not support choline deficiency as a clinically significant cause of eye disease in adults, despite intriguing preliminary research suggesting potential future relevance.